Philip M Grant1, Aoife G Cotter. 1. aDivision of Infectious Diseases; Department of Medicine; Stanford University, Palo Alto, CA, USA bHIV Molecular Research Group, School of Medicine & Medical Science, University College Dublin cDepartment of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland.
Abstract
PURPOSE OF REVIEW: With continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more recent bone data on tenofovir alafenamide. RECENT FINDING: Several studies have demonstrated an approximately 1-3% greater bone mineral density loss with TDF compared with other agents. Recent studies with tenofovir alafenamide have shown improved bone (and renal) safety with similar virologic efficacy when compared to TDF. SUMMARY: Given these findings, TDF-containing regimens may be gradually replaced with non-TDF containing regimens for the treatment of HIV infection, especially in those at higher risk for fragility fracture.
PURPOSE OF REVIEW: With continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more recent bone data on tenofovir alafenamide. RECENT FINDING: Several studies have demonstrated an approximately 1-3% greater bone mineral density loss with TDF compared with other agents. Recent studies with tenofovir alafenamide have shown improved bone (and renal) safety with similar virologic efficacy when compared to TDF. SUMMARY: Given these findings, TDF-containing regimens may be gradually replaced with non-TDF containing regimens for the treatment of HIV infection, especially in those at higher risk for fragility fracture.
Authors: Mar Masiá; Sergio Padilla; Catalina Robledano; Natividad López; José Manuel Ramos; Felix Gutiérrez Journal: AIDS Res Hum Retroviruses Date: 2011-07-19 Impact factor: 2.205
Authors: Andrew M Hall; Simon G Edwards; Marta Lapsley; John O Connolly; Kreesan Chetty; Stephen O'Farrell; Robert J Unwin; Ian G Williams Journal: Am J Kidney Dis Date: 2009-09-23 Impact factor: 8.860
Authors: Clare L N Woodward; A M Hall; I G Williams; S Madge; A Copas; D Nair; S G Edwards; M A Johnson; J O Connolly Journal: HIV Med Date: 2009-05-06 Impact factor: 3.180
Authors: José R Valdez Madruga; Isabel Cassetti; Jamal Muhamad A H Suleiman; Arnaldo Etzel; Lijie Zhong; Charles B Holmes; Andrew K Cheng; Jeffrey Enejosa Journal: HIV Clin Trials Date: 2007 Nov-Dec
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Lisa Hamzah; Juan M Tiraboschi; Helen Iveson; Martina Toby; Christine Mant; John Cason; Keith Burling; Emily Wandolo; Isabelle Jendrulek; Chris Taylor; Fowzia Ibrahim; Ranjababu Kulasegaram; Alastair Teague; Frank A Post; Julie Fox Journal: Antivir Ther Date: 2015-10-13
Authors: Jose I Bernardino; Amanda Mocroft; Patrick W Mallon; Cedrick Wallet; Jan Gerstoft; Charlotte Russell; Peter Reiss; Christine Katlama; Stephane De Wit; Laura Richert; Abdel Babiker; Antonio Buño; Antonella Castagna; Pierre-Marie Girard; Genevieve Chene; Francois Raffi; Jose R Arribas Journal: Lancet HIV Date: 2015-09-30 Impact factor: 12.767
Authors: Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.771
Authors: Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister Journal: Lancet Infect Dis Date: 2015-11-02 Impact factor: 25.071
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Stanzi M le Roux; Jennifer Jao; Kirsty Brittain; Tamsin K Phillips; Seun Olatunbosun; Agnes Ronan; Allison Zerbe; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2017-01-02 Impact factor: 4.177
Authors: Theresa W Kim; Alexander Y Walley; Alicia S Ventura; Gregory J Patts; Timothy C Heeren; Gabriel B Lerner; Nicholas Mauricio; Richard Saitz Journal: AIDS Care Date: 2017-10-16
Authors: Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Jessie K Edwards; Stephen R Cole; Tiffany L Breger; Jacqueline E Rudolph; Lindsey M Filiatreau; Kate Buchacz; Elizabeth Humes; Peter F Rebeiro; Gypsyamber D'Souza; M John Gill; Michael J Silverberg; W Christopher Mathews; Michael A Horberg; Jennifer Thorne; H Irene Hall; Amy Justice; Vincent C Marconi; Viviane D Lima; Ronald J Bosch; Timothy R Sterling; Keri N Althoff; Richard D Moore; Michael Saag; Joseph J Eron Journal: Ann Intern Med Date: 2021-07-06 Impact factor: 25.391